The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The Parkinson Progression Marker Initiative (PPMI)
Open accessAbstract
The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multicenter study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials. The PPMI cohort will comprise 400 recently diagnosed PD and 200 healthy subjects followed longitudinally for clinical, imaging and biospecimen biomarker assessment using standardized data acquisition protocols at twenty-one clinical sites. All study data will be integrated in the PPMI study database and will be rapidly and publically available through the PPMI web site- www.ppmi-info.org. Biological samples including longitudinal collection of blood, cerebrospinal fluid (CSF) and urine will be available to scientists by application to an independent PPMI biospecimen review committee also through the PPMI web site. PPMI will rely on a partnership of government, PD foundations, industry and academics working cooperatively. This approach is crucial to enhance the potential for success of this ambitious strategy to develop PD progression biomarkers that will accelerate research in disease modifying therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationLevodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Self-citationSlower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Self-citationEl‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715
The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans
Weiner, M. W., Aisen, P. S., Jack, C. R., Jagust, W. J., Trojanowski, J. Q., Shaw, L., Saykin, A. J., Morris, J. C., Cairns, N., Beckett, L. A., et al. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.007 · Cited by 599
Self-citationThe parkinson's complex: Parkinsonism is just the tip of the iceberg
Langston, J. W. (2006) · Annals of Neurology · doi:10.1002/ana.20834 · Cited by 583
Invited Article: Nervous system pathology in sporadic Parkinson disease
Braak, H., & Del Tredici, K. (2008) · Neurology · doi:10.1212/01.wnl.0000312279.49272.9f · Cited by 538
Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans
Aisen, P. S., Petersen, R. C., Donohue, M. C., Gamst, A., Raman, R., Thomas, R. G., Walter, S., Trojanowski, J. Q., Shaw, L. M., Beckett, L. A., et al. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.006 · Cited by 517
Self-citationMolecular markers of early Parkinson's disease based on gene expression in blood
Scherzer, C. R., Eklund, A. C., Morse, L. J., Liao, Z., Locascio, J. J., Fefer, D., Schwarzschild, M. A., Schlossmacher, M. G., Hauser, M. A., Vance, J. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610204104 · Cited by 512
Self-citationHigh-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease
Vaillancourt, D. E., Spraker, M. B., Prodoehl, J., Abraham, I., Corcos, D. M., Zhou, X. J., Comella, C. L., & Little, D. M. (2009) · Neurology · doi:10.1212/01.wnl.0000340982.01727.6e · Cited by 438
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature
Péran, P., Cherubini, A., Assogna, F., Piras, F., Quattrocchi, C., Peppe, A., Celsis, P., Rascol, O., Démonet, J.-F., Stefani, A., et al. (2010) · Brain · doi:10.1093/brain/awq212 · Cited by 399
CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
Siderowf, A., Xie, S. X., Hurtig, H., Weintraub, D., Duda, J., Chen-Plotkin, A., Shaw, L. M., Van Deerlin, V., Trojanowski, J. Q., & Clark, C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39a78 · Cited by 378
Self-citationThe role of radiotracer imaging in Parkinson disease
Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000149403.14458.7f · Cited by 374
Self-citationUpdate on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
Trojanowski, J. Q., Vandeerstichele, H., Korecka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.008 · Cited by 307
Self-citationProgression of Parkinson's disease in the clinical phase: potential markers
Maetzler, W., Liepelt, I., & Berg, D. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70291-1 · Cited by 305
Self-citationSTRIATONIGRAL DEGENERATION: A CLINICOPATHOLOGICAL STUDY
FEARNLEY, J. M., & LEES, A. J. (1990) · Brain · doi:10.1093/brain/113.6.1823 · Cited by 296
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
The Parkinson Study Group PRECEPT Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000277648.63931.c0 · Cited by 292
Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder
Klein, C., & Schlossmacher, M. G. (2007) · Neurology · doi:10.1212/01.wnl.0000271880.27321.a7 · Cited by 211
MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE
Wang, L. H., & Johnson, E. M. (2008) · Neurology · doi:10.1212/01.wnl.0000324506.93877.5e · Cited by 204
Why have we failed to achieve neuroprotection in Parkinson's disease?
Olanow, C. W., Kieburtz, K., & Schapira, A. H. V. (2009) · Annals of Neurology · doi:10.1002/ana.21461 · Cited by 183
Self-citationCSF Aβ42 and tau in Parkinson's disease with cognitive impairment
Montine, T. J., Shi, M., Quinn, J. F., Peskind, E. R., Craft, S., Ginghina, C., Chung, K. A., Kim, H., Galasko, D. R., Jankovic, J., et al. (2010) · Movement Disorders · doi:10.1002/mds.23287 · Cited by 182
Self-citationOlanow, C. W., Schapira, A. H., LeWitt, P. A., Kieburtz, K., Sauer, D., Olivieri, G., Pohlmann, H., & Hubble, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70602-0 · Cited by 178
Self-citationGray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies
Beyer, M. K., Larsen, J. P., & Aarsland, D. (2007) · Neurology · doi:10.1212/01.wnl.0000269666.62598.1c · Cited by 174
Assessment of the progression of Parkinson's disease: a metabolic network approach
Eckert, T., Tang, C., & Eidelberg, D. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70245-4 · Cited by 162
Colosimo, C., Martínez‐Martín, P., Fabbrini, G., Hauser, R. A., Merello, M., Miyasaki, J. M., Poewe, W. H., Sampaio, C., Rascol, O., Stebbins, G. T., et al. (2010) · Movement Disorders · doi:10.1002/mds.23072 · Cited by 121
Self-citationBiomarker discovery in neurodegenerative diseases: A proteomic approach
Shi, M. Y., Caudle, W. M., & Zhang, J. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.09.004 · Cited by 115
Can we image premotor Parkinson disease?
MAREK, K. L., & Jennings, D. L. (2009) · Neurology · doi:10.1212/wnl.0b013e318198df97 · Cited by 93
Self-citationDisease modification in Parkinson's disease
Schapira, A. H. V. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00769-0 · Cited by 74
Safety of Lumbar Puncture Procedures in Patients with Alzheimers Disease
Peskind, E., Nordberg, A., Darreh-Shori, T., & Soininen, H. (2009) · Current Alzheimer Research · doi:10.2174/156720509788486509 · Cited by 66
Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression
MAREK, K. L., Jennings, D. L., Tamagnan, G. D., & Seibyl, J. P. (2009) · Annals of Neurology · doi:10.1002/ana.21602 · Cited by 64
Self-citationA longitudinal program for biomarker development in Parkinson's disease: A feasibility study
Ravina, B. M., Tanner, C. M., DiEuliis, D., Eberly, S. W., Flagg, E., Galpern, W. R., Fahn, S., Goetz, C. G., Grate, S. J., Kurlan, R., et al. (2009) · Movement Disorders · doi:10.1002/mds.22690 · Cited by 61
Self-citationNeurochemical biomarkers in the differential diagnosis of movement disorders
Mollenhauer, B., & Trenkwalder, C. (2009) · Movement Disorders · doi:10.1002/mds.22510 · Cited by 46
Self-citationRationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study
Schapira, A., Albrecht, S., Barone, P., Comella, C., McDermott, M., Mizuno, Y., Poewe, W., Rascol, O., & Marek, K. (2010) · Movement Disorders · doi:10.1002/mds.23143 · Cited by 41
Self-citationEarly Detection of Parkinson’s Disease: Unmet Needs
Gerlach, M., Hendrich, A., Hueber, R., Jost, W. H., Winkler, J., Woitalla, D., & Riederer, P. F. (2008) · Neurodegenerative Diseases · doi:10.1159/000113683 · Cited by 13
Schmidt, M. E., Siemers, E., Snyder, P. J., Potter, W. Z., Cole, P. E., & Soares, H. D. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.010 · Cited by 11
The Role of the Core Imaging Laboratory in Multicenter Trials
Seibyl, J. P., MAREK, K. L., & Zubal, I. G. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2010.03.002 · Cited by 10
Self-citation
Research works printed but not linked: 3
- Jankovic, 1990, Lower body (vascular) parkinsonism, Arch. Neurol., 47, 728, 10.1001/archneur.1990.00530070014003 · doi:10.1001/archneur.1990.00530070014003
- The Lancet, 2010, Biomarker promise for Parkinson's disease, Lancet Neurol., 9, 1139, 10.1016/S1474-4422(10)70284-2 · doi:10.1016/s1474-4422(10)70284-2
- Vornov, 2006, GPI 1485, a neuroimmunophilin ligand, fails to alter disease progression in mild to moderate Parkinson's disease, Mov. Disord.
Cited by
VoxelMorph: A Learning Framework for Deformable Medical Image Registration
Balakrishnan, G., Zhao, A., Sabuncu, M. R., Guttag, J., & Dalca, A. V. (2019) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2019.2897538 · Cited by 2,174
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
Irwin, D. J., Lee, V. M.-Y., & Trojanowski, J. Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3549 · Cited by 869
Self-citationDiffusion models in medical imaging: A comprehensive survey
Kazerouni, A., Aghdam, E. K., Heidari, M., Azad, R., Fayyaz, M., Hacihaliloglu, I., & Merhof, D. (2023) · Medical Image Analysis · doi:10.1016/j.media.2023.102846 · Cited by 765
Lead-DBS v2: Towards a comprehensive pipeline for deep brain stimulation imaging
Horn, A., Li, N., Dembek, T. A., Kappel, A., Boulay, C., Ewert, S., Tietze, A., Husch, A., Perera, T., Neumann, W.-J., et al. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2018.08.068 · Cited by 739
CSF and blood biomarkers for Parkinson's disease
Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., & Calabresi, P. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30024-9 · Cited by 673
Self-citation
Metadata
- Authors
- Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., Poewe, W., Mollenhauer, B., Klinik, P.-E., Sherer, T., Frasier, M., Meunier, C., Rudolph, A., Casaceli, C., Seibyl, J., Mendick, S., Schuff, N., Zhang, Y., Toga, A., Crawford, K., Ansbach, A., De Blasio, P., Piovella, M., Trojanowski, J., Shaw, L., Singleton, A., Hawkins, K., Eberling, J., Brooks, D., Russell, D., Leary, L., Factor, S., Sommerfeld, B., Hogarth, P., Pighetti, E., Williams, K., Standaert, D., Guthrie, S., Hauser, R., Delgado, H., Jankovic, J., Hunter, C., Stern, M., Tran, B., Leverenz, J., Baca, M., Frank, S., Thomas, C.-A., Richard, I., Deeley, C., Rees, L., Sprenger, F., Lang, E., Shill, H., Obradov, S., Fernandez, H., Winters, A., Berg, D., Gauss, K., Galasko, D., Fontaine, D., Mari, Z., Gerstenhaber, M., Brooks, D., Malloy, S., Barone, P., Longo, K., Comery, T., Ravina, B., Grachev, I., Gallagher, K., Collins, M., Widnell, K. L., Ostrowizki, S., Fontoura, P., Ho, T., Luthman, J., Brug, M. V. D., Reith, A. D., & Taylor, P.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 95
- Issue
- 4
- Pages
- 629-635
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W1988494453
- Cited by
- 1,892
- References
- 40
- FWCI
- 15.73
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.